NCT03318653 (DIALBP) is a clinical trial in End Stage Renal Disease, sponsored by PD Dr. Grégoire Wuerzner.

Who is sponsoring NCT03318653?

NCT03318653 is sponsored by PD Dr. Grégoire Wuerzner.

What condition does NCT03318653 study?

NCT03318653 studies End Stage Renal Disease.

Is NCT03318653 still recruiting?

NCT03318653 is currently completed. Last updated 16 March 2018.

Last reviewed 2018-03-16 · How we verify

NCT03318653: DIALBP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blood Pressure Measurement in Dialysed Patients

Completed Last updated 16 March 2018

What this trial tests

trial in End Stage Renal Disease in 192 participants. Completed in 15 March 2018.

Timeline

20 June 2017

Primary endpoint
15 March 2018

15 March 2018

Quick facts

Lead sponsor	PD Dr. Grégoire Wuerzner
Status	Completed
Study type	OBSERVATIONAL
Enrollment	192
Start date	20 June 2017
Primary completion	15 March 2018
Estimated completion	15 March 2018
Sites	1 location across Switzerland

Conditions studied

End Stage Renal Disease — all drugs for End Stage Renal Disease →

Sponsor

PD Dr. Grégoire Wuerzner

Who can join

Eligibility, any sex, with End Stage Renal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the current study is to evaluate the compliance to blood pressure measurements' recommendations in dialysis centers. The idea is to address a questionnaire to physicians, head nurses and patients in order to probe the way to measure blood pressure. The objective is to face the theoretical guideline with what is effectively done.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for End Stage Renal Disease

Currently open trials in the same condition.

NCT06257134 — Impact on Quality of Life of Symptoms Routine E-monitoring Among Dialysis Patients. · NA · recruiting
NCT06310161 — Light Therapy in End Stage Kidney Disease · NA · recruiting
NCT07360938 — Drug Interaction Potential of Pro-Inflammatory Conditions · recruiting
NCT06422871 — PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis · recruiting
NCT06861816 — Ventilatory Functions and Physical Intolerance in ESRD Adolescents: Response to Program of Walking With Dogs · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03318653 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PD Dr. Grégoire Wuerzner
Last refreshed: 16 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03318653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing